Physician

Shuo Ma, M.D., PH.D.

According to 2025 Medicare claims, Shuo Ma, M.D., PH.D. (NPI: 1659564938) practices hematology in the Chicago-Naperville-Schaumburg, IL market, with the plurality of this provider's patient population coming from Cook, IL. This provider's primary affiliated billing organization is NORTHWESTERN MEDICAL FACULTY FOUNDATION (NPI: 1346235314; TIN: 363097297) and primary practice location at 60611-2027. Ma is affiliated with the Northwestern Medicine Physician Network ACO (ACO ID: A2620), participating under the MSSP model.

Ma's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 554 traditional Medicare patients, billed 44,985 HCPCS/CPT codes, and received $1,212,651 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 826 prescription claims across 176 beneficiaries totaling $3,615,939 in drug costs, led by Brukinsa (Zanubrutinib). 2020 DME data shows 11 claims. Open Payments data shows 330 records totaling $7,055,987. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $156,559 to $3,615,939. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	441	49,036	$1,318,856
2016	538	75,576	$1,982,737
2017	495	60,083	$1,658,475
2018	554	63,578	$2,098,432
2019	632	81,746	$2,063,744
2020	597	83,120	$2,572,467
2021	696	129,573	$3,964,009
2022	756	150,075	$3,946,957
2023	709	95,436	$2,554,296
2024	554	44,985	$1,212,651

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	62	207	$156,559
2016	79	409	$1,100,776
2017	76	372	$1,566,249
2018	84	350	$847,585
2019	127	627	$2,465,731
2020	137	960	$5,011,164
2021	155	948	$4,109,284
2022	161	805	$2,020,744
2023	157	761	$2,847,014
2024	176	826	$3,615,939

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	11	$2,134
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	94	197	$143
96413	Administration of chemotherapy into vein, 1 hour or less	89	105	$104
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	311	887	$96
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	264	516	$13
96375	Injection of additional new drug or substance into vein	70	121	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Brukinsa	Zanubrutinib	117	3,540	$1,471,527
Calquence	Acalabrutinib Maleate	97	2,910	$1,447,060
Venclexta	Venetoclax	25	790	$350,659
Promacta	Eltrombopag Olamine	13	390	$174,132
Eliquis	Apixaban	19	780	$15,030

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	41	$44,650	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	289	$7,011,337	BeiGene, Ltd.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Shuo Ma, M.D., PH.D.?

Tedicare shows public-source Medicare data for Shuo Ma, M.D., PH.D. (NPI 1659564938), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Shuo Ma, M.D., PH.D. have ACO affiliation data?

Shuo Ma, M.D., PH.D. is shown with ACO affiliation data for Northwestern Medicine Physician Network ACO (MSSP, ACO ID A2620).

What billing organization is linked to Shuo Ma, M.D., PH.D.?

Shuo Ma, M.D., PH.D. is linked to NORTHWESTERN MEDICAL FACULTY FOUNDATION (billing NPI 1346235314) in the available physician profile data.

Does Shuo Ma, M.D., PH.D. have Open Payments data?

Shuo Ma, M.D., PH.D. has 330 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.